<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00213083</url>
  </required_header>
  <id_info>
    <org_study_id>Population Council #322</org_study_id>
    <nct_id>NCT00213083</nct_id>
  </id_info>
  <brief_title>Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission</brief_title>
  <official_title>Phase 3 Study of the Efficacy and Safety of the Microbicide Carraguard速 in Preventing HIV Seroconversion in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Council</source>
  <brief_summary>
    <textblock>
      The purposes of this study are to determine whether Carraguard速 Gel can prevent the
      transmission of HIV when used during vaginal intercourse, and to confirm that the gel is safe
      for vaginal use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to show if Carraguard速 can protect women against HIV if it is used
      before sex, and is safe for long-term use.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to HIV seroconversion during trial participation (evaluated quarterly)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine long-term safety based on the incidence of sexually transmitted infections (STI), Chlamydia, gonorrhoeae, trichomoniasis, and syphilis tests and the number of adverse events and serious adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chlamydia, gonorrhoeae, trichomoniasis and syphilis tests are conducted at months 3, 6, 12, 18 and 24 and as clinically indicated</measure>
  </secondary_outcome>
  <enrollment type="Actual">6203</enrollment>
  <condition>HIV Infections</condition>
  <condition>AIDS</condition>
  <condition>Sexually Transmitted Diseases</condition>
  <condition>HIV Seroconversion</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carraguard (PC-515)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV negative and agree to be tested for HIV and told their results at all visits
             during the study

          -  Aged 16 - 40 years of age

          -  Have had at least one vaginal intercourse within the last three months

          -  Willing and able to give written informed consent (or if desired, consent provided by
             parent or guardian with written assent from the minor participant)

          -  Provide locator information to study staff throughout the trial

          -  Comply with all aspects of the study protocol, including random assignment to the
             Carraguard速 plus condom or placebo plus condom arm, clinical valuations, specimen
             collection and testing, visit schedule and study drug regimen

          -  Citizen or permanent resident of South Africa

          -  Resident for the past year and intends to reside in the catchment area of the site for
             the next two years

          -  During the study, will not use any vaginal products except tampons or those prescribed
             or approved by the study clinician.

        Exclusion Criteria:

          -  Currently pregnant, or indicate a desire to become pregnant in the next two years at
             the time of screening

          -  Within four weeks of last pregnancy outcome at the time of enrolment

          -  Pap smear at screening is graded as carcinoma.

          -  Injected illicit drugs in the 12 months prior to screening

          -  Participating in any other clinical trial/HIV prevention study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pekka Lahteenmaki, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Council, Center for Biomedical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Isipingo Clinic</name>
      <address>
        <city>Overport</city>
        <state>Durban</state>
        <zip>4067</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Empilisweni Clinic</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Clinic, University of Limpopo - Medunsa Campus</name>
      <address>
        <city>Medunsa</city>
        <zip>0204</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://www.popcouncil.org</url>
    <description>Official website of the Population Council</description>
  </link>
  <reference>
    <citation>Skoler S, Govender S, Altini L, Ahmed K, Waldron D, Myer L, Lahteenmaki P. Risks in the use of an unblinded-control group. J Infect Dis. 2005 Apr 15;191(8):1378-9; author reply 1379-80.</citation>
    <PMID>15776387</PMID>
  </reference>
  <reference>
    <citation>Wallace AR, Teitelbaum A, Wan L, Mulima MG, Guichard L, Skoler S, Vilakazi H, Mapula FS, Rossier J, Govender SN, Lahteenmaki P, Maguire RA, Phillips DM. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007 Jul;76(1):53-6. Epub 2007 May 11. Erratum in: Contraception. 2007 Oct;76(4):335. Skiler, Stephanie [corrected to Skoler, Stephanie].</citation>
    <PMID>17586138</PMID>
  </reference>
  <reference>
    <citation>Singh JA, Karim SS, Karim QA, Mlisana K, Williamson C, Gray C, Govender M, Gray A. Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa. PLoS Med. 2006 Jul;3(7):e180. Epub 2006 Apr 18.</citation>
    <PMID>16608384</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>August 11, 2017</last_update_submitted>
  <last_update_submitted_qc>August 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbicide</keyword>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>STIs</keyword>
  <keyword>STDs</keyword>
  <keyword>Efficacy</keyword>
  <keyword>HSV</keyword>
  <keyword>Women</keyword>
  <keyword>South Africa</keyword>
  <keyword>seroconversion</keyword>
  <keyword>condom</keyword>
  <keyword>safe-sex</keyword>
  <keyword>vaginal intercourse</keyword>
  <keyword>prevention</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

